Three partners in the development of diabetes drug Bydureon - Amylin (AMLN), Alkermes (ALKS) and...

|By:, SA News Editor

Three partners in the development of diabetes drug Bydureon - Amylin (AMLN), Alkermes (ALKS) and Eli Lilly (LLY) - say the treatment didn’t slow heart rate in further testing requested last year by the FDA. ALKS +1.4%, AMLN +6.9%, LLY -0.7% premarket. (PR)